

Summary of the June 2015 Gavi Alliance Board Meeting

Gavi Partner Engagement Framework (PEF): The Gavi Alliance Board approved changes to the new modus operandi of the Alliance with targeted and innovative investments across the Alliance partnership through the new Partners Engagement Framework (PEF). A lot of emphasis was made by the Board on the high expectations in achieving the Alliance's coverage and equity objectives, with increased accountability and in ensuring successful transition of countries. The supporting decisions include:

- **Approved** commitments in an annual amount of US\$ 31.2 million for the Foundational Support for partners (UNICEF, CDC, World Bank, CSO constituency and WHO) in the years 2016 and 2017 and, subject to satisfactory performance, in the annual amount of US\$ 31.2 million for the Foundational Support for partners in the years 2018-2020.
- **Approved** annual commitments in an annual amount of US\$ 5.2 million for the Foundational Support for IPV introduction in the years 2016 and 2017 for WHO and UNICEF. The Board commended the huge amount of work by partners to facilitate over 100 IPV introductions in 2015.

Transition Support to Countries: The Board approved new policies allowing graduated Gavi countries to be included in UNICEF tenders for specific vaccines, with the aim of continuing to provide them with access to Gavi prices for a five year period. This is within the scope of the WHO lead strategy for supporting Middle Income Countries endorsed by the SAGE in April and aims at ensuring access to affordable vaccines for all Gavi supported countries. The supporting decisions include:

- **Approved** changes to the current co-financing and transition support policies providing a time-limited opportunity to access exceptional catalytic support for the introduction of HPV, MR and/or JE vaccines for those Phase 2 countries that did not have the possibility to apply for these vaccines, due to the timing of the vaccines' availability.
- **Approved** the Alliance's approach to ensuring access to appropriate pricing for Phase 3 [graduated] Gavi countries by continuing to seek appropriate and sustainable prices through market shaping activities consistent with Gavi's Vaccine Supply and Procurement Strategy. Furthermore, allowing Phase 3 [graduated] Gavi countries to be included in UNICEF tenders on behalf of Gavi-eligible and Phase 2 [graduating] countries for specific vaccines with the aim of continuing to provide them with access to Gavi prices for a five year period (provided a country commits to key terms to be defined by UNICEF and Gavi).
- **Approved** providing a catalytic investment of US\$ 5 million towards the capitalisation of UNICEF's Vaccine Independence Initiative (VII), a revolving fund which supports timely availability of financing for countries to meeting payment terms. The use of this investment will be prioritised towards Gavi countries, subject to UNICEF approval of each country application to participate in VII.

Innovative Cold Chain Platform: the Board approved the creation of an innovative mechanism to strengthen country cold chain systems and advance the Alliance's Supply Chain Strategy and, ultimately, its coverage and equity goals (the "CCE platform") with an initial allocation of US\$ 50 million for 2016-2020.

Gavi Support to Ebola: Board members were informed that a lot of work had already taken place in relation to vaccine deployment and of the strategy being developed for SAGE to consider. The Board highlighted that one of the main priorities now in the affected countries will be to work on restoring routine immunisation services.

Sustainable Development Goal Indicators: The Board raised concerns regarding the latest IAEG SDG indicator meeting report with no mention of vaccines and immunisation and committed to continue advocacy efforts to ensure critical inclusion of GVAP coverage indicator.